在一项针对2型糖尿病患者的临床试验中,礼来公司研发的口服GLP-1药物Orforglipron,在血糖控制和体重减轻方面均表现出优于口服司美格鲁肽的疗效。
在一项针对2型糖尿病患者的临床试验中,礼来公司研发的口服GLP-1药物Orforglipron,在血糖控制和体重减轻方面均表现出优于口服司美格鲁肽的疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.